در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Iranian Journal of Immunology
- نوع مقاله: Journal Article
- کلمات کلیدی: Lymphocytes,Macrophages,Effector-target Conjugate,Cytotoxic Reactions,Zymosan,Betaglucan
- چکیده:
- چکیده انگلیسی: Background: Polysaccharides have long been used as immune-modulators in various pathologic conditions including inflammation and solid malignancies.
Objective: To evaluate the effects of Zymosan and Betaglucan on cytotoxic reactions in an effectortarget conjugate system.
Methods: Blood was obtained from 20 healthy subjects; purified mononuclear leukocytes (monocytes and lymphocytes) were extracted and cultured as effector cells by a cytotoxic method. Both adherent and non-adherent cells interacted with the K562 myeloid cell line. The effector-target (E:T) ratio was 1:1, 1:10, and 1:20. To evaluate stimulatory effects of Betaglucan and Zymosan on cytotoxic reactions, samples were divided into case and control groups based on the presence or absence of Betaglucan and Zymosan. MTT assay and sFas ligand (sFasL) concentrations were used to assess the increased killing capacity of effector cells.
Results: Our results revealed that Zymosan and Betaglucan can induce cytotoxic responses in macrophages and lymphocytes (P<0.05). The best result was achieved with E:T ratio of 1:1. Both macrophages and lymphocytes produced sFasL following stimulation by Zymosan and Betaglucan, however, the level of production was not statistically significant (P>0.05).
Conclusion: Zymosan and Betaglucan can be used as enhancers of the killing capacity of the immune cells; therefore, Betaglucan and Zymosan can be applied as systemic stimulators of the immune response in inflammation and chronic infection.- انتشار مقاله: 16-05-1395
- نویسندگان: Ziba Ghasemi,Babak Farrokhi,Farah Miraghasi,Ardalan Ejaz Ahmad,Nariman Mosaffa
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Anaplastic thyroid carcinoma,CD133 antigen,Phosphoinositide-3-kinase,Sodium-iodide symporter
- چکیده:
- چکیده انگلیسی:
Background: Thyroidectomy, radioactive iodine therapy, chemotherapy, or their combination are treatments of choice for thyroid cancers. However, cancer stem cells (CSCs) may become resistant to therapy, and mutations in somatic genes affect radioiodine uptake. This study determined the effect of a phosphoinositide-3-kinase (PI3K) inhibitor on anaplastic thyroid CSCs. Materials and Methods: The magnetic-activated cell sorting assay was used for segregating CD133-positive CSCs from three anaplastic thyroid carcinoma (ATC) cell lines (C643, SW1736, and 8305C). After confirming the cells’ purity by flow cytometry, they were treated with 5, 10, 20, or 25 μM LY294002, a PI3K inhibitor, and then evaluated at 24 and 48 h. The sodium-iodide symporter (NIS) mRNA level was determined using the quantitative real-time polymerase chain reaction. NIS protein expression was evaluated using western blotting. Results: The PI3K inhibitor, at different concentrations and times, increased the NIS mRNA level (1.30-6.17-fold, P < 0.0001). If the NIS mRNA level in LY294002-treated CD133-positive CSCs was increased more than 2-fold, the NIS protein content was detectable. Conclusions: CD133-positive CSCs isolated from ATC cell lines expressed NIS mRNA and protein after PI3K inhibition. Our findings suggest that molecularly targeted CSC therapy may improve the treatment efficacy of aggressive cancers like ATC.- انتشار مقاله: 27-03-1396
- نویسندگان: Farzaneh Bozorg-Ghalati,Mehdi Hedayati,Mehdi Dianatpour,Fereidoun Azizi,Nariman Mosaffa,Davood Mehrabani
- مشاهده